KR101205289B1 - Ｇ-250 발현 종양의 개선된 보조제 요법 - Google Patents

Ｇ-250 발현 종양의 개선된 보조제 요법 Download PDF

Info

Publication number
KR101205289B1
KR101205289B1 KR1020067027704A KR20067027704A KR101205289B1 KR 101205289 B1 KR101205289 B1 KR 101205289B1 KR 1020067027704 A KR1020067027704 A KR 1020067027704A KR 20067027704 A KR20067027704 A KR 20067027704A KR 101205289 B1 KR101205289 B1 KR 101205289B1
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
antibody
antigen
cancer
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020067027704A
Other languages
English (en)
Korean (ko)
Other versions
KR20070036085A (ko
Inventor
올라프 빌헬름
스벤 와르나아르
Original Assignee
빌렉스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 빌렉스 아게 filed Critical 빌렉스 아게
Publication of KR20070036085A publication Critical patent/KR20070036085A/ko
Application granted granted Critical
Publication of KR101205289B1 publication Critical patent/KR101205289B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020067027704A 2004-07-02 2005-06-29 Ｇ-250 발현 종양의 개선된 보조제 요법 Expired - Fee Related KR101205289B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58467904P 2004-07-02 2004-07-02
US60/584,679 2004-07-02
PCT/EP2005/006994 WO2006002889A2 (en) 2004-07-02 2005-06-29 Improved adjuvant therapy of g250-expressing tumors

Publications (2)

Publication Number Publication Date
KR20070036085A KR20070036085A (ko) 2007-04-02
KR101205289B1 true KR101205289B1 (ko) 2012-11-27

Family

ID=35431139

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020067027704A Expired - Fee Related KR101205289B1 (ko) 2004-07-02 2005-06-29 Ｇ-250 발현 종양의 개선된 보조제 요법

Country Status (13)

Country Link
US (1) US7691375B2 (https=)
EP (2) EP1763367A2 (https=)
JP (1) JP2008505143A (https=)
KR (1) KR101205289B1 (https=)
CN (1) CN101052416B (https=)
AU (1) AU2005259481B2 (https=)
BR (1) BRPI0512854A (https=)
CA (1) CA2566950A1 (https=)
DK (1) DK2497497T3 (https=)
ES (1) ES2641089T3 (https=)
MX (1) MXPA06013240A (https=)
RU (2) RU2371198C2 (https=)
WO (1) WO2006002889A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077081A1 (en) * 2001-02-07 2004-04-22 Egbert Oosterwijk Hybridoma cell line g250 and its use for producing monoclonal antibodies
US20090162382A1 (en) * 2002-03-01 2009-06-25 Bernett Matthew J Optimized ca9 antibodies and methods of using the same
US7632496B2 (en) * 2002-07-01 2009-12-15 Wilex Ag Co-administration of cG250 and IL-2 or IFN-α for treating cancer such as renal cell carcinomas
KR20120082429A (ko) 2009-09-18 2012-07-23 미쓰비시 가가꾸 가부시키가이샤 간세포암 마커
RU2442983C1 (ru) * 2011-01-14 2012-02-20 Государственное учреждение здравоохранения Научно-исследовательский институт скорой помощи имени Н.В. Склифосовского Департамента здравоохранения г. Москвы Способ прогнозирования безрецидивной выживаемости по молекулярным факторам у больных с метастазами колоректального рака в печени после ее резекции
MX338711B (es) 2012-10-12 2016-04-28 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas.
BR112015020061A8 (pt) * 2013-02-22 2018-01-23 Wilex Ag composto alvo anidrase carbônica ix (caix) para tratamento de câncer, seus usos, composição farmcêutica, e método para diagnosticar, prognosticar e/ou classificar um câncer
MX362970B (es) 2013-03-13 2019-02-28 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas.
EP3193940A1 (en) 2014-09-10 2017-07-26 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
EP3525829A1 (en) 2016-10-11 2019-08-21 Medimmune Limited Antibody-drug conjugates with immune-mediated therapy agents
CA3098103A1 (en) 2018-05-23 2019-11-28 Adc Therapeutics Sa Molecular adjuvant
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
EP4426727A2 (en) 2021-11-03 2024-09-11 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002062972A2 (en) 2001-02-07 2002-08-15 Wilex Ag Hybridoma cell line g250 and its use for producing monoclonal antibodies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0366707A1 (en) * 1987-05-06 1990-05-09 OOSTERWIJK, Egbert Monoclonal antibodies to renal cell carcinoma
US5387676A (en) * 1992-03-11 1995-02-07 Ciba Corning Diagnostics Corp. MN gene and protein
US6417337B1 (en) * 1996-10-31 2002-07-09 The Dow Chemical Company High affinity humanized anti-CEA monoclonal antibodies
JP2006500905A (ja) * 2002-02-13 2006-01-12 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ ヒト化ｇｍ−ｃｓｆ抗体
US7632496B2 (en) * 2002-07-01 2009-12-15 Wilex Ag Co-administration of cG250 and IL-2 or IFN-α for treating cancer such as renal cell carcinomas
RU2257200C1 (ru) * 2004-05-12 2005-07-27 Кутушов Михаил Владимирович Лекарственное средство

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002062972A2 (en) 2001-02-07 2002-08-15 Wilex Ag Hybridoma cell line g250 and its use for producing monoclonal antibodies

Also Published As

Publication number Publication date
CA2566950A1 (en) 2006-01-12
BRPI0512854A (pt) 2008-04-08
RU2371198C2 (ru) 2009-10-27
EP2497497A1 (en) 2012-09-12
JP2008505143A (ja) 2008-02-21
US20070207157A1 (en) 2007-09-06
EP1763367A2 (en) 2007-03-21
RU2519340C2 (ru) 2014-06-10
EP2497497B1 (en) 2017-06-21
MXPA06013240A (es) 2007-02-28
CN101052416A (zh) 2007-10-10
KR20070036085A (ko) 2007-04-02
AU2005259481A1 (en) 2006-01-12
CN101052416B (zh) 2013-07-10
RU2009122344A (ru) 2010-12-20
US7691375B2 (en) 2010-04-06
ES2641089T3 (es) 2017-11-07
WO2006002889A2 (en) 2006-01-12
DK2497497T3 (en) 2017-08-14
WO2006002889A3 (en) 2006-10-05
RU2007104040A (ru) 2008-08-10
AU2005259481B2 (en) 2010-04-22

Similar Documents

Publication Publication Date Title
RU2519340C2 (ru) Улучшенная вспомогательная терапия опухолей, экспрессирующих g250
US9556271B2 (en) Anti-CEACAM1 recombinant antibodies for cancer therapy
CN108026173A (zh) 通过联合阻断pd-1和cxcr4信号传导途径治疗癌症
AU2018241099A1 (en) Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
JP4857259B2 (ja) 癌細胞増殖を阻害するための抗α５β１抗体の使用
JP2022058699A (ja) 再発性小細胞肺癌の処置方法において使用するための抗ｐｄ－１抗体
CN112972675A (zh) 抗pd-1抗体在治疗肿瘤中的用途
CN115066260A (zh) 抗pd-1抗体在治疗恶性肿瘤中的用途
TW201811369A (zh) Mek抑制劑、pd-1軸抑制劑及vegf抑制劑之組合療法
CN112292151A (zh) 抗pd-1抗体在制备治疗实体瘤的药物中的用途
CN115052628B (zh) 抗pd-1抗体在治疗肿瘤中的用途
CN115052629A (zh) 抗pd-1抗体在治疗神经内分泌瘤中的用途
CN112915203B (zh) 喹啉衍生物与pd-1单抗的药物组合
CN1933851B (zh) 使用抗-α5β1抗体抑制癌细胞增殖
RU2361614C2 (ru) ПРИМЕНЕНИЕ АНТИТЕЛ ПРОТИВ α5β1 ДЛЯ ИНГИБИРОВАНИЯ ПРОЛИФЕРАЦИИ РАКОВЫХ КЛЕТОК
HK1101348B (en) Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation
Plimack et al. Kidney cancer
Fontenot et al. A Novel Monoclonal Antibody to Secreted Frizzled-Related Protein
HK40002353A (en) Methods of treating skin cancer by administering a pd-1 inhibitor

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20151112

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20161111

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20171109

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20181109

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20191122

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20191122